USA - NASDAQ:VTRS - US92556V1061 - Common Stock
We assign a fundamental rating of 4 out of 10 to VTRS. VTRS was compared to 191 industry peers in the Pharmaceuticals industry. There are concerns on the financial health of VTRS while its profitability can be described as average. VTRS has a bad growth rate and is valued cheaply.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -9.03% | ||
ROE | -22.27% | ||
ROIC | 3.61% |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | 10.13% | ||
PM (TTM) | N/A | ||
GM | 40.15% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.82 | ||
Debt/FCF | 7.49 | ||
Altman-Z | 0.89 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 1.37 | ||
Quick Ratio | 0.77 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 4.28 | ||
Fwd PE | 4.14 |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | 7.04 | ||
EV/EBITDA | 5.7 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | 4.75% |
10.31
+0.14 (+1.38%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | 4.75% |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 4.28 | ||
Fwd PE | 4.14 | ||
P/S | 0.85 | ||
P/FCF | 7.04 | ||
P/OCF | 5.82 | ||
P/B | 0.77 | ||
P/tB | N/A | ||
EV/EBITDA | 5.7 |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -9.03% | ||
ROE | -22.27% | ||
ROCE | 4.57% | ||
ROIC | 3.61% | ||
ROICexc | 3.69% | ||
ROICexgc | 14.98% | ||
OM | 10.13% | ||
PM (TTM) | N/A | ||
GM | 40.15% | ||
FCFM | 12.1% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.82 | ||
Debt/FCF | 7.49 | ||
Debt/EBITDA | 3.05 | ||
Cap/Depr | 12.94% | ||
Cap/Sales | 2.53% | ||
Interest Coverage | 250 | ||
Cash Conversion | 49.28% | ||
Profit Quality | N/A | ||
Current Ratio | 1.37 | ||
Quick Ratio | 0.77 | ||
Altman-Z | 0.89 |